Fully human antibodies that bind to vascular endothelial growth factor receptor 2 (VEGFR2)
AssigneeSorrento Therapeutics, Inc.
InventorsRandy Gastwirt, Heyue Zhou, John Dixon Gray, Guodi Lu
Life of this patent
Estimating the term…
Abstract
There is disclosed compositions and methods relating to anti-VEGFR2 antibodies. More specifically, there is disclosed fully human antibodies that bind VEGFR2, VEGFR2-binding fragments and derivatives of such antibodies, and VEGFR2-binding polypeptides comprising such fragments. Further still, there is disclosed antibody fragments and derivatives and polypeptides, and methods of using such antibodies, antibody fragments and derivatives and polypeptides, including methods of treating or diagnosing subjects having various cancers.
Claims12
A recombinant fully human anti-vascular endothelial growth factor receptor 2 (VEGFR2) antibody, or an antigen binding fragment thereof, that binds to VEGFR2 comprising complementarity determining regions (CDRs) as set forth in a heavy chain variable domain amino acid sequence selected from the group consisting of SEQ ID NO. 9, SEQ ID NO. 23, SEQ ID NO. 51, SEQ ID NO. 63, SEQ ID NO. 73 and SEQ ID NO. 77, and comprising CDRs as set forth in a light chain variable domain amino acid sequence selected from the group consisting of SEQ ID NO. 10, SEQ ID NO. 24, SEQ ID NO. 52, SEQ ID NO. 64, SEQ ID NO. 78, and SEQ ID NO. 81.
Dependencies are inferred from the claim text.